Vor Biopharma Inc.

Vor Biopharma Inc.

VOR·NASDAQ

$13.44

-0.037%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$92.12M
EPS-70.5000
P/E Ratio-0.19
Earnings Date08/11/2026

vor

Additional Paid-In Capital

Last Annual Value

988.60M

3-Year CAGR

28%

5-Year CAGR

241%

10-Year CAGR

126%

Vor Biopharma Inc.

Vor Biopharma Inc. Competitors Analysis of Additional Paid-In Capital

VOR · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
988.60M
26.3%23.3%N/A 
284.35M
22.7%19.9%N/A
510.03M
0.8%2.3%N/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
657.29M
4.0%3.6%7.8%
1.44B
1.4%4.7%10.0%
702.98M
17.8%10.9%32.5%
0.00
N/AN/AN/A
1.95B
1.4%2.9%13.2%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
433.18M
7.0%N/AN/A
416.08M
9.5%34.4%N/A
498.69M
22.9%14.3%9.7%
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR · NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.44, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

Intrinsic Value
Current Price: $13.44